Breaking News: U.S. FDA Approves Roflumilast Cream 0.05% for AD in Kids Aged 2 to 5
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for roflumilast cream 0.05% (Zoryve, Arcutis) for the topical treatment of mild-to-moderate atopic dermatitis (AD) in children aged 2 to 5. Arcutis intends to make roflumilast cream 0.05% widely available via key wholesaler and pharmacy channels as a new treatment […]